Secondary Myelofibrosis Clinical Trials

42 clinical trials for Secondary Myelofibrosis across international registries, including 7 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs) — RECRUITING · PHASE2
• Reduced Intensity Haploidentical Transplantation for the Treatment of Primary or Secondary Myelofibrosis — RECRUITING · PHASE2
• Research Platform Myelofibrosis and Anemia — RECRUITING
• Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms — RECRUITING · PHASE2
• Ruxolitinib Before, During and After Hematopoietic Cell Transplant in Older Patients With Myelofibrosis and Myelodysplastic Syndrome/Myeloproliferative Neoplasm Overlap Syndromes — RECRUITING · PHASE2
• MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myeloproliferative Neoplasms (MPNs) — RECRUITING
• Ruxolitinib in Primary Myelofibrosis and Secondary to Essential Thrombocythemia or Polycythemia Vera — RECRUITING
• Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Secondary Myelofibrosis — ACTIVE_NOT_RECRUITING · PHASE1
• Adding Itacitinib to Cyclophosphamide and Tacrolimus for the Prevention of Graft Versus Host Disease in Patients Undergoing Hematopoietic Stem Cell Transplants — ACTIVE_NOT_RECRUITING · PHASE2
• Decitabine in Treating Patients With Myelofibrosis — ACTIVE_NOT_RECRUITING · PHASE2
• Peritransplant Ruxolitinib for Patients With Primary and Secondary Myelofibrosis — ACTIVE_NOT_RECRUITING · PHASE2
• Fedratinib in Combination With Nivolumab — COMPLETED · PHASE2
• Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms — ACTIVE_NOT_RECRUITING · PHASE1
• Itacitinib, Tacrolimus, and Sirolimus for the Prevention of GVHD in Patients With Acute Leukemia, Myelodysplastic Syndrome, or Myelofibrosis Undergoing Reduced Intensity Conditioning Donor Stem Cell Transplantation — COMPLETED · PHASE2
• JAK Inhibitor Before Donor Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis — COMPLETED · PHASE2
• Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant — ACTIVE_NOT_RECRUITING
• P1101 in Treating Patients With Myelofibrosis — TERMINATED · PHASE2
• Ruxolitinib and Pomalidomide Combination Therapy in Patients With Primary and Secondary MF — COMPLETED · PHASE1
• Ruxolitinib Phosphate and Chemotherapy Given Before and After Reduced Intensity Donor Stem Cell Transplant in Treating Patients With Myelofibrosis — COMPLETED · PHASE1
• Busulfan, Cyclophosphamide, & Antithymocyte Globulin Followed by Stem Cell Transplant in Treating Hematologic Cancer — COMPLETED · PHASE2
• LCL161 in Treating Patients With Primary Myelofibrosis, Post-Polycythemia Vera Myelofibrosis, or Post-Essential Thrombocytosis Myelofibrosis — COMPLETED · PHASE2
• Allogeneic Stem Cell Transplantation for Multiple Myeloma and Myelofibrosis — TERMINATED · PHASE2
• Imetelstat Sodium in Treating Participants With Primary or Secondary Myelofibrosis — COMPLETED · PHASE2
• Pemetrexed Disodium in the Cerebrospinal Fluid of Patients With Leptomeningeal Metastases — COMPLETED · PHASE1
• Combination Chemotherapy, Total Body Irradiation, and Donor Blood Stem Cell Transplant in Treating Patients With Primary or Secondary Myelofibrosis — COMPLETED · PHASE1
• CC-4047 in Treating Patients With Myelofibrosis — COMPLETED · PHASE1
• Management of Platelet Transfusion Therapy in Patients With Blood Cancer or Treatment-Induced Thrombocytopenia — TERMINATED · PHASE2
• Fludarabine Phosphate, Melphalan, and Low-Dose Total-Body Irradiation Followed by Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies — COMPLETED · PHASE2
• Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies — COMPLETED · PHASE2
• Deferasirox in Treating Iron Overload Caused By Blood Transfusions in Patients With Hematologic Malignancies — COMPLETED · PHASE2
• Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome — COMPLETED · NA
• Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases — TERMINATED · PHASE1
• Ruxolitinib Phosphate and Danazol in Treating Anemia in Patients With Myelofibrosis — COMPLETED · PHASE2
• T-Cell Depletion, Donor Hematopoietic Stem Cell Transplant (HSCT), and T-Cell Infusions in Treating Patients With Hematologic Cancer or Other Diseases — TERMINATED · PHASE2
• Ruxolitinib Phosphate, Tacrolimus and Sirolimus in Preventing Acute Graft-versus-Host Disease During Reduced Intensity Donor Hematopoietic Cell Transplant in Patients With Myelofibrosis — WITHDRAWN · PHASE1
• Reversible Secondary Myelofibrosis or Clonal Myeloproliferative Disorder — TERMINATED
• Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease — TERMINATED
• Low-Dose Decitabine in Treating Patients With Symptomatic Myelofibrosis — TERMINATED · PHASE2
• Sirolimus, Tacrolimus, and Antithymocyte Globulin in Preventing Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant For Hematological Cancer — COMPLETED · PHASE2
• Sibling Donor Peripheral Stem Cell Transplant or Sibling Donor Bone Marrow Transplant in Treating Patients With Hematologic Cancers or Other Diseases — COMPLETED · PHASE3
• Azacitidine in Treating Patients With Myelofibrosis — TERMINATED · PHASE2
• Thalidomide, Prednisone, and Cyclophosphamide in Treating Patients With Myelofibrosis and Myeloid Metaplasia — COMPLETED · PHASE2

Refine this search